Arrayit Corp.’s (ARYC.OB) Proteomic Biomarkers to Enable Pre-Symptomatic Ovarian Cancer Testing
Arrayit Corp., the Sunnyvale, California-based developer of life science technologies, proudly announced today the capacity for the first time ever for a genuine, pre-symptomatic diagnostic methodology for Ovarian Cancer via the Company’s proprietary OvaDx™ proteomic biomarker. The biomarker field is a complex one, wrought with a certain amount of confusion as a result. One issue of contention right now is where the biomarkers derive from. Typically, biomarkers are taken from tumors in patients who already have cancer, but ARYC’s patented methodology allows for first-time-ever pre-symptomatic diagnosis, taking biomarkers not from tumors but from the patient’s own immunological response to preliminary…